Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 10, 2014; 5(3): 299-310
Published online Aug 10, 2014. doi: 10.5306/wjco.v5.i3.299
Published online Aug 10, 2014. doi: 10.5306/wjco.v5.i3.299
Evolution of breast cancer therapeutics: Breast tumour kinase’s role in breast cancer and hope for breast tumour kinase targeted therapy
Haroon A Hussain, Amanda J Harvey, Brunel Institute for Cancer Genetics and Pharmacogenomics, Biosciences, Brunel University (London), Uxbridge UB8 3PH, United Kingdom
Author contributions: Hussain HA wrote the first draft under guidance from Harvey AJ; both authors have edited the manuscript.
Correspondence to: Dr. Amanda J Harvey, Brunel Institute for Cancer Genetics and Pharmacogenomics, Biosciences, Brunel University (London), Kingston Lane, Uxbridge, Middlesex, UB 8 3PH, United Kingdom. amanda.harvey@brunel.ac.uk
Telephone: +44-0-1895267264 Fax: +44-0-1895269873
Received: December 20, 2013
Revised: May 20, 2014
Accepted: May 31, 2014
Published online: August 10, 2014
Revised: May 20, 2014
Accepted: May 31, 2014
Published online: August 10, 2014
Core Tip
Core tip: Breast tumour kinase/protein tyrosine kinase 6 is overexpressed in up to 86% of invasive breast cancers. It plays a key role in regulating a number of cell processes that are involved in the metastatic process. As a kinase involved in both epidermal growth factor and insulin like growth factors signaling, inhibiting its activity could prove to be an effective way to enhance the effects of current targeted treatments. In addition, disrupting the protein-protein interactions central for the kinase-independent aspects of its function may generate an alternative mechanism for selective targeting of breast cancer cells.